{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:04:48Z","timestamp":1789535088628,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most prevalent chronic liver condition globally, yet its prospective association with incident type 2 diabetes mellitus (T2DM) in the general health check-up population requires further elucidation. This study aimed to investigate whether baseline MAFLD increases the risk of new-onset T2DM in a health check-up cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective cohort study initially screened 1,520 individuals from the health check-up database; after applying strict exclusion criteria (including baseline T2DM, other liver diseases, malignancy, missing key data, and loss to follow-up), 186 participants without baseline T2DM were finally included. These participants underwent annual health examinations at Shanxi Bethune Hospital Health Check-up Center from 2020 to 2024. Baseline anthropometric measurements, biochemical parameters, and medical histories were collected. The primary outcome was new-onset T2DM over 5\u202fyears. Associations were analyzed using Kaplan\u2013Meier methods and multivariable Cox regression. The primary analysis was adjusted for age, sex, and body mass index (BMI); a fully adjusted model including additional metabolic covariates was performed as a sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a median 60-month follow-up, 22 new T2DM cases occurred. The 5-year cumulative incidence of T2DM was significantly higher in the MAFLD group than in the non-MAFLD group (18.9% vs. 5.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001). Multivariable Cox regression suggested that MAFLD was associated with an increased risk of new-onset T2DM (adjusted HR\u202f=\u202f3.15, 95%CI: 1.58\u20136.28,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001 for age, sex, and BMI; a fully adjusted sensitivity analysis yielded HR\u202f=\u202f2.71, 95%CI: 1.33\u20135.52,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006), with preliminary findings for both lean MAFLD (HR\u202f=\u202f2.88, 95%CI: 1.10\u20137.54, based on a small subgroup of 15 participants) and overweight\/obese MAFLD (HR\u202f=\u202f2.65, 95%CI: 1.22\u20135.76, both from fully adjusted sensitivity models). Sensitivity and stratified analyses were generally consistent with the primary association, although the small number of events in subgroup analyses limited the statistical power and precluded definitive conclusions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline MAFLD may be associated with an increased risk of new-onset T2DM within 5\u202fyears in a health check-up population, although these preliminary findings require confirmation in larger studies. Both lean and overweight\/obese MAFLD subtypes showed associations with an elevated risk of T2DM in exploratory analyses, although the finding for lean MAFLD (based on only 15 individuals and 3 T2DM events) should be considered hypothesis-generating and preliminary and requires validation in larger cohorts. Early screening and lifestyle interventions for individuals with MAFLD are of paramount clinical importance for diabetes prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1881173","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:09Z","timestamp":1789533249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic dysfunction-associated fatty liver disease increases the risk of new-onset type 2 diabetes mellitus: a retrospective cohort study based on health check-up data"],"prefix":"10.3389","volume":"13","author":[{"given":"Lihua","family":"Sun","sequence":"first","affiliation":[{"name":"Health Management Center, Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences Tongji Shanxi Hospital), Third Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"Health Management Center, Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences Tongji Shanxi Hospital), Third Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Health Management Center, Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences Tongji Shanxi Hospital), Third Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1001\/jama.2021.22208","article-title":"Prevalence and treatment of diabetes in China, 2013-2018","volume":"326","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","article-title":"Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention","volume":"21","author":"Zhou","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","article-title":"The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux","volume":"126","author":"Samuel","year":"2016","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3350\/cmh.2023.0485","article-title":"Global incidence of adverse clinical events in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"30","author":"Le","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S2468-1253(25)00188-8","article-title":"Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis","volume":"10","author":"Celsa","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a Nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"105706","DOI":"10.4254\/wjh.v17.i5.105706","article-title":"Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: a meta-analysis","volume":"17","author":"Shetty","year":"2025","journal-title":"World J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1002\/hep4.1969","article-title":"Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents","volume":"6","author":"Ciardullo","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.3748\/wjg.v30.i43.4682","article-title":"Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: new frontiers in metabolic dysfunction-associated steatotic liver disease therapy","volume":"30","author":"Guney-Coskun","year":"2024","journal-title":"World J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41575-025-01142-z","article-title":"Mechanistic insights into the liver-brain axis during chronic liver disease","volume":"23","author":"Siddle","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.cld.2023.01.001","article-title":"Nonalcoholic fatty liver disease: disease burden and disease awareness","volume":"27","author":"Golabi","year":"2023","journal-title":"Clin Liver Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1881173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:17Z","timestamp":1789533257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1881173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1881173"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1881173","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1881173"}}